Tacrolimus could suppress PVR development

Article

Application of intravitreal tacrolimus could suppress the development of proliferative vitreoretinopathy (PVR).

Application of intravitreal tacrolimus could suppress the development of proliferative vitreoretinopathy (PVR), reveals a paper in Retina.

The investigation, led by Dr Burak Turgut, Department of Ophthalmology, Firat University School of Medicine, Elazig, Turkey, consisted of 21 guinea pigs randomly and evenly assigned to three groups. The groups included a non-PVR group injected with saline, a dispase-induced PVR group injected with saline and a dispase-induced PVR group injected with tacrolimus.

Eyes were enucleated after the investigation and the stages of PVR were identified. Halves of the enucleated globes were histopathologically evaluated for PVR formation and the retinas of the other halves of globes were used to prepare retinal homogenates. The enzyme-linked immunsorbent assay method was used to measure transforming growth factor-β, platelet-derived growth factor, and fibroblast growth factor levels in homogenized retina tissues.

The average PVR stages in the tacrolimus group significantly improved compared to the PVR-saline group. The tacrolimus group also presented with lower levels of transforming growth factor-β, platelet-derived growth factor and fibroblast growth factor. Significant improvement was identified in epiretinal membrane formation and retinal fold in the tacrolimus group.

The study implies that tacrolimus could be helpful towards investigating the prophylaxis of PVR.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.